Since the 1940’s when Pfizer first mass-produced penicillin, we’ve been actively involved in the discovery and development of medicines to treat infections as well as vaccines that prevent them.

We have over 80 anti-infective medicines and vaccines in our portfolio, and continue to evaluate opportunities to expand our R&D pipeline to ensure we address the evolving medical needs of patients and healthcare workers. This includes helping to tackle antimicrobial resistance (AMR), where micro-organisms which cause infection (e.g. bacteria) survive exposure to a medicine that would normally kill them or stop their growth.